AstraZeneca shared the topline result from the placebo-controlled ... before AZ and its partner Merck were able to cross the ...

The FTSE 100 index is seen opening eight points higher at 8034, having fallen 1.2% to a three-month low in yesterday’s ...

AstraZeneca, Daiichi Sankyo seek US FDA’s accelerated approval for datopotamab deruxtecan to treat advanced EGFR-mutated NSCLC ...

On the results front, AstraZeneca is among the heavyweight companies in the spotlight. However, the biggest share price moves ...

As the company restructures, it will pivot to selling genetic tests to consumers and using that data for research. Also: medicinal and tech advancements in cancer care; research monkeys roundup.

The two parties, together with AstraZeneca, will cooperate on scientific research ... Health Engineering was established ...

Daiichi Sankyo collaboration AstraZeneca and Daiichi Sankyo entered into a global collaboration to jointly develop and commercialise Enhertu (trastuzumab deruxtecan) in March 2019 and datopotamab ...

Despite China’s investigations into insurance fraud, allegedly illegal importation of unapproved drugs and improper ...

AstraZeneca chief executive Pascal Soriot said the company took the detention of its China president “very seriously”, as the drugmaker raised its guidance for a second straight quarter on the back of ...

AstraZeneca has upgraded its revenue and earnings guidance for this year. Total revenues and core earnings per share rose 21% ...

AstraZeneca raises its fiscal 2024 guidance for the second consecutive quarter. This upgrade comes despite ongoing legal ...